Novartis' (NVS) PKC412 NDA Granted FDA Priority Review as AML Treatment
Go back to Novartis' (NVS) PKC412 NDA Granted FDA Priority Review as AML Treatment| NOVARTIS AG (NYSE: NVS) | Delayed: 98.35 +1.07 (1.10%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $97.28 | 52 Week High | $89.15 | |||
| Open | $98.50 | 52 Week Low | $69.84 | |||
| Day High | $98.55 | P/E | N/A | |||
| Day Low | $97.41 | EPS | $0.00 | |||
| Volume | 2,233,162 | |||||
